TY - JOUR
T1 - Myeloablative allogeneic hematopoietic stem cell transplantation for non-Hodgkin lymphoma
T2 - A nationwide survey in Japan
AU - Kim, Sung Won
AU - Tanimoto, Tetsuya E.
AU - Hirabayashi, Noriyuki
AU - Goto, Seiichi
AU - Kami, Masahiro
AU - Yoshioka, Satoshi
AU - Uchida, Toshiki
AU - Kishi, Kenji
AU - Tanaka, Yuji
AU - Kohno, Akio
AU - Kasai, Masaharu
AU - Higuchi, Masakazu
AU - Kasai, Masanobu
AU - Mori, Shin Ichiro
AU - Fukuda, Takahiro
AU - Izutsu, Koji
AU - Sao, Hiroshi
AU - Ishikawa, Takayuki
AU - Ichinohe, Tatsuo
AU - Takeuchi, Kengo
AU - Tajima, Kinuko
AU - Tanosaki, Ryuji
AU - Harada, Mine
AU - Taniguchi, Shuichi
AU - Tobinai, Kensei
AU - Hotta, Tomomitsu
AU - Takaue, Yoichi
N1 - Copyright:
Copyright 2008 Elsevier B.V., All rights reserved.
PY - 2006/7/1
Y1 - 2006/7/1
N2 - We retrospectively surveyed the data of 233 patients who underwent myeloablative allogeneic hematopoietic stem cell transplantation (allo-HSCT) for non-Hodgkin lymphoma (NHL). Donors were HLA-matched relatives in 154 patients (66%) or unrelated volunteers in 60 (26%). Ninety patients (39%) were in complete remission. One hundred ninety-three (83%) received a total body irradiation (TBI)-based regimen, and 40 (17%) received a non-TBI-based regimen. Acute graft-versus-host disease (GVHD) occurred in 155 (67%) of the 233 evaluable patients; grade II to IV in 90 (39%), and grade III to IV in 37 (16%). Treatment-related mortality (TRM) was observed in 98 patients (42%), and 68% of them were related to GVHD. In a multivariate analysis, chemoresistance, prior autograft, and chronic GVHD were identified as adverse prognostic factors for TRM. Relapse or progression of lymphoma was observed in 21%. The 2-year overall survival rates of the patients with indolent (n = 38), aggressive (n = 111), and lymphoblastic lymphoma (n = 84) were 57%, 42%, and 41%, respectively. In a multivariate analysis, chemoresistance, prior autograft, and prior radiotherapy were identified as adverse prognostic factors for overall survival. Although myeloablative allo-HSCT represents an effective therapeutic option for patients with NHL, more work is still needed to decrease TRM and relapse.
AB - We retrospectively surveyed the data of 233 patients who underwent myeloablative allogeneic hematopoietic stem cell transplantation (allo-HSCT) for non-Hodgkin lymphoma (NHL). Donors were HLA-matched relatives in 154 patients (66%) or unrelated volunteers in 60 (26%). Ninety patients (39%) were in complete remission. One hundred ninety-three (83%) received a total body irradiation (TBI)-based regimen, and 40 (17%) received a non-TBI-based regimen. Acute graft-versus-host disease (GVHD) occurred in 155 (67%) of the 233 evaluable patients; grade II to IV in 90 (39%), and grade III to IV in 37 (16%). Treatment-related mortality (TRM) was observed in 98 patients (42%), and 68% of them were related to GVHD. In a multivariate analysis, chemoresistance, prior autograft, and chronic GVHD were identified as adverse prognostic factors for TRM. Relapse or progression of lymphoma was observed in 21%. The 2-year overall survival rates of the patients with indolent (n = 38), aggressive (n = 111), and lymphoblastic lymphoma (n = 84) were 57%, 42%, and 41%, respectively. In a multivariate analysis, chemoresistance, prior autograft, and prior radiotherapy were identified as adverse prognostic factors for overall survival. Although myeloablative allo-HSCT represents an effective therapeutic option for patients with NHL, more work is still needed to decrease TRM and relapse.
UR - http://www.scopus.com/inward/record.url?scp=33745627072&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33745627072&partnerID=8YFLogxK
U2 - 10.1182/blood-2005-02-0596
DO - 10.1182/blood-2005-02-0596
M3 - Review article
C2 - 16522821
AN - SCOPUS:33745627072
VL - 108
SP - 382
EP - 389
JO - Blood
JF - Blood
SN - 0006-4971
IS - 1
ER -